SCHEMBL21648795

SCHEMBL21648795

CNCC1(F)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27064828 0.88
SCHEMBL23891928 0.86 SLC6A4 (0.42)
SCHEMBL12205329 0.82 KDM1A (0.40)
SCHEMBL23323156 0.82
SCHEMBL15739795 0.80 KDM1A (0.44)
SCHEMBL25640277 0.75 CYP2D6 (0.35)
SCHEMBL20296417 0.75
SCHEMBL24818437 0.75
SCHEMBL9173925 0.73
SCHEMBL25640281 0.72 KCNH2 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023086495-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2023-05-19 WO disclosed
WO-2023056441-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2023-04-06 WO disclosed
WO-2020023782-A1 BIFUNCTIONAL COMPOUNDS AS CDK MODULATORS BIOTHERYX, INC. (US) 2020-01-30 WO disclosed